Centro de Investigación Médica Aplicada-ko ikertzaileekin lankidetzan egindako argitalpenak (29)

2024

  1. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  2. Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer

    Cell Death Discovery, Vol. 10, Núm. 1

2022

  1. Explainable artificial intelligence for precision medicine in acute myeloid leukemia

    Frontiers in Immunology, Vol. 13

  2. Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma

    Frontiers in Immunology, Vol. 13

2021

  1. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with in Vivo Efficacy in Multiple Myeloma

    Journal of Medicinal Chemistry, Vol. 64, Núm. 6, pp. 3392-3426

  2. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

2019

  1. HDAC inhibitors in acute myeloid leukemia

    Cancers, Vol. 11, Núm. 11

  2. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

2018

  1. COBRA methods and metabolic drug targets in cancer

    Molecular and Cellular Oncology, Vol. 5, Núm. 1

  2. Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells

    Oncotarget, Vol. 9, Núm. 16, pp. 12842-12852

  3. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6546-6573

  4. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6518-6545

2017

  1. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism

    Nature Communications, Vol. 8, Núm. 1

  2. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

  3. Dual epigenetic modifiers for cancer therapy

    Molecular and Cellular Oncology, Vol. 4, Núm. 4

  4. In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer

    Scientific Reports, Vol. 7, Núm. 1

  5. Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome

    PLoS ONE, Vol. 12, Núm. 12

2015

  1. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

    Genome Research, Vol. 25, Núm. 4, pp. 478-487

2013

  1. Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia

    Epigenomics, Vol. 5, Núm. 5, pp. 525-538